133 related articles for article (PubMed ID: 6411336)
1. Pharmacokinetics of mitomycin C in humans.
den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intraarterial mitomycin C in humans.
Hu E; Howell SB
Cancer Res; 1983 Sep; 43(9):4474-7. PubMed ID: 6409404
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Sugarbaker PH; Stuart OA; Carmignani CP
Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres.
Rump AF; Woschée U; Theisohn M; Fischbach R; Heindel W; Lackner K; Klaus W
Eur J Clin Pharmacol; 2002 Oct; 58(7):459-65. PubMed ID: 12389068
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
van Hazel GA; Scott M; Rubin J; Moertel CG; Eagan RT; O'Connell MJ; Kovach JS
Cancer Treat Rep; 1983 Sep; 67(9):805-10. PubMed ID: 6411337
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vincristine sulfate in adult cancer patients.
Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
14. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
[TBL] [Abstract][Full Text] [Related]
15. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Takahashi K; Yokoyama M; Takahashi H; Wakui A
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
17. The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.
Verweij J; Stuurman M; de Vries J; Pinedo HM
J Cancer Res Clin Oncol; 1986; 112(3):283-4. PubMed ID: 3097025
[TBL] [Abstract][Full Text] [Related]
18. Distribution and excretion of 7-N-(p-hydroxyphenyl)-mitomycin C in normal mice.
Imai R; Morimoto M; Marumo H
Gan; 1982 Aug; 73(4):675-80. PubMed ID: 6818093
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
20. Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers.
Strocchi E; Iaffaioli RV; Facchini G; Mantovani G; Ricci S; Cavallo G; Tortoriello A; D'Angelo R; Formato R; Rosato G; Fiore F; Iaccarino V; Petrella G; Memoli B; Santangelo M; Camaggi CM
Eur J Surg Oncol; 2004 Aug; 30(6):663-70. PubMed ID: 15256242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
